Management of Post-Chemotherapy Induced Thrombocytopenia in Pancreatic Cancer

Initial Assessment

The American Society of Clinical Oncology recommends ruling out drug-induced immune thrombocytopenia, particularly with oxaliplatin-containing regimens, before implementing platelet-based management strategies 2
Assess bleeding risk factors, including concurrent coagulopathy, liver or renal impairment, infection, tumor location, and need for invasive procedures, as recommended by the European Society for Medical Oncology 2, 3

For patients with platelets ≥50,000/μL, the National Comprehensive Cancer Network recommends continuing full-dose chemotherapy without modification 1, 4
For patients with platelets 25,000-50,000/μL, the American College of Clinical Pharmacy suggests considering thrombopoietin receptor agonists to maintain platelet counts and allow continuation of full-dose chemotherapy 1, 3
For patients with platelets <25,000/μL, the European Society for Medical Oncology recommends temporarily discontinuing chemotherapy and providing supportive care 1

For patients with concurrent venous thromboembolism, the International Society on Thrombosis and Haemostasis recommends full therapeutic anticoagulation with low-molecular-weight heparin (LMWH) for platelets ≥50,000/μL, reduced LMWH dose for platelets 25-50,000/μL, and temporary discontinuation of anticoagulation for platelets <25,000/μL 1, 3
The American College of Chest Physicians advises against using direct oral anticoagulants in pancreatic cancer patients with thrombocytopenia due to increased bleeding risk 1